A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection
- PMID: 32206188
- PMCID: PMC7075466
- DOI: 10.18632/oncotarget.27496
A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection
Abstract
Resectable pancreatic adenocarcinoma (PC) is generally managed with surgery followed by chemotherapy, but the role of postoperative chemoradiation (pCRT) is controversial. We sought to identify a microRNA (miRNA) expression profile associated with higher risk for local-regional recurrence (LRR), which might help identify patients that may benefit from pCRT. Total RNA was isolated from viable tumor from 88 patients who underwent PC resection with or without chemotherapy, but did not receive radiation. Digital miRNA expression profiling was performed and risk scores were calculated based on the expression levels of the four most significantly correlated miRNAs, and dichotomized about the median to detect correlations between risk group, LRR and overall survival (OS). Two cohorts from The Cancer Genome Atlas (TCGA) and Seoul National University (SNU) were used for validation. Patients with high-risk scores had significantly worse LRR (p = 0.001) and worse OS (p = 0.034). Two-year OS rates for the high- and low-risk groups were 27.7% and 52.2%, respectively. On multivariable analysis, the risk score remained significantly associated with LRR (p = 0.018). When validated on TCGA data, a high-risk score was associated with worse OS on univariate (p = 0.03) and multivariable analysis (p = 0.017). When validated on the SNU cohort, a high-risk score was likewise associated with worse OS (p = 0.042). We have developed a 4-miRNA molecular signature that is associated with risk of LRR and OS after PC resection and validated on two separate cohorts. This signature has the potential to select patients most likely to benefit from pCRT, and should be tested further.
Keywords: local-regional recurrence; miRNA; non-coding RNA; pancreatic cancer; prognostic biomarker.
Copyright: © 2020 Wolfe et al.
Conflict of interest statement
CONFLICTS OF INTEREST No potential conflicts of interest.
Figures



Similar articles
-
Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma.Cancers (Basel). 2021 Oct 15;13(20):5168. doi: 10.3390/cancers13205168. Cancers (Basel). 2021. PMID: 34680317 Free PMC article.
-
A novel microRNA signature predicts survival in stomach adenocarcinoma.Oncotarget. 2017 Apr 25;8(17):28144-28153. doi: 10.18632/oncotarget.15961. Oncotarget. 2017. PMID: 28423653 Free PMC article.
-
A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer.Oncotarget. 2016 Oct 25;7(43):69616-69624. doi: 10.18632/oncotarget.11903. Oncotarget. 2016. PMID: 27626307 Free PMC article.
-
A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data.Sci Rep. 2018 May 16;8(1):7638. doi: 10.1038/s41598-018-22493-5. Sci Rep. 2018. PMID: 29769534 Free PMC article.
-
Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.BMC Genomics. 2015 Sep 29;16:735. doi: 10.1186/s12864-015-1899-0. BMC Genomics. 2015. PMID: 26416693 Free PMC article.
Cited by
-
Serum miRNA Profiling for Early PDAC Diagnosis and Prognosis: A Retrospective Study.Biomedicines. 2021 Jul 20;9(7):845. doi: 10.3390/biomedicines9070845. Biomedicines. 2021. PMID: 34356909 Free PMC article.
-
MicroRNAs: emerging biomarkers and therapeutic targets in pancreatic cancer.Front Mol Biosci. 2024 Sep 3;11:1457875. doi: 10.3389/fmolb.2024.1457875. eCollection 2024. Front Mol Biosci. 2024. PMID: 39290995 Free PMC article. Review.
-
A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma.PeerJ. 2020 Nov 26;8:e10418. doi: 10.7717/peerj.10418. eCollection 2020. PeerJ. 2020. PMID: 33304656 Free PMC article.
-
The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer.Cancers (Basel). 2020 Dec 9;12(12):3703. doi: 10.3390/cancers12123703. Cancers (Basel). 2020. PMID: 33317198 Free PMC article.
-
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy.Radiat Oncol. 2023 Aug 18;18(1):137. doi: 10.1186/s13014-023-02328-y. Radiat Oncol. 2023. PMID: 37596627 Free PMC article. Review.
References
-
- Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310:1473–81. 10.1001/jama.2013.279201. - DOI - PubMed
-
- Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, et al. , and Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379:2395–406. 10.1056/NEJMoa1809775. - DOI - PubMed
-
- Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, et al. , and JASPAC 01 Study Group . Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388:248–57. 10.1016/S0140-6736(16)30583-9. - DOI - PubMed
LinkOut - more resources
Full Text Sources